Home > Press > 50 Early- to Late-Stage Medical Device Companies Seeking Investment and Partnering Opportunities to Present in 3 Weeks at ''Investment In Innovation
Abstract:
June 17-19, 2008, The Palace Hotel, San Francisco, CA
Medtech Insight, a division of Windhover Information, Inc. and a leading provider of business information for the medical device industry, has announced that more than 40 early- to late-stage medical technology companies seeking funding and/or strategic partnership are confirmed to date to present at its "Investment In Innovation (In3) Medical Device Summit," taking place June 17-19, 2008 at The Palace Hotel in San Francisco, California, out of approximately 50 to present in all. Twenty of these companies are making their first appearance on the In3 stage. The In3 Summit, the company's largest strategic partnership and investment conference for medical technology executives, the is the most important venue of its kind for previewing cutting-edge emerging medtech companies and engaging with the biggest dealmakers in the industry, including senior executives from the device industry and healthcare investment community.
Conference highlights will include company presentations focused into 3 concurrent tracks, each followed by break-out sessions in private conference rooms. The 3 tracks will consist of early- to late-stage cardiovascular and peripheral vascular companies, orthopedics and spine companies, and other high-growth technology areas such as device coatings/infection control, diabetes management, diagnostics, endoscopic technology, imaging, incontinence products, nanotechnology, oncology diagnostics and therapeutics, ophthalmic surgery, pain management, reproduction management, and tissue engineering, among others.
Track 1 (Cardio/Peripheral Vascular) presenters to date include Arterial Remodeling Technologies, CardiAQ Valve Technologies, Cardiola, Ltd., Cardiva Medical, Inc., Emergence LLC, ES Vascular Ltd., Genesis Medical Interventional, Interventional and Surgical Innovations, LLC, Neochord, Inc., PROTOMED, Tayside Flow Technologies Limited, Thornhill Research Inc., and Tissue Genetics. Track 2 (Ortho/Spine) presenters confirmed to date include Argo Medical Technologies Ltd., Bone Biologics, Inc., Echometrix, LLC, Emergence LLC, Innova Orthopaedics, Ortho Kinematics, and Orthovita, Inc. Track 3 (Other High-Growth Technologies) presenting companies to date include Altascience Limited, Ceragenix Pharmaceuticals, CVAC Systems, Inc., Envisionier Medical Technologies, EyeGate Pharmaceuticals, Inc., Gel Delivery Solutions BV, GlucoLight Corporation, Healionics Corporation, InfraScan, Inc., Keraderm LLC, MicroPhage, Inc., MoleMap, Nanobiotix, Novian Health Inc., Photo Dynamic Therapy, Polymedix, Inc., Provista Life Sciences, LLC, Softscope Medical Technologies, Symbios Medical, Vasorum Ltd., and Vironova AB.
The In3 Summit's growing attendee list includes a robust line-up of buy-side/investors from around the world. A sample of companies sending their teams include: 3M, Abbott Laboratories, Accuitive Medical Ventures, Aubrey Group, Inc., Averion, Becton Dickinson, BioQuest, Boston Biomedical Associates, Cardinal Health, Cook Group, Inc., Coronis Medical Ventures, Covidien, C.R. Bard, Inc., Delphi Ventures, Dow Europe, DuPont BioSciences, Easton Associates, Edwards Lifesciences Corporation, Emergent Medical Ventures, Essex Woodlands Venture Partners, Ethicon Endo-Surgery, Inc., F-D-C Reports, Inc., FMR Group, Foster-Miller, Inc., Frazier Healthcare Ventures, GM Medical Pacific Ltd., HLM Venture Partners, Invest In Germany, Johnson & Johnson, Kaiser Permanente Ventures, MachVentures, LLC, Matignon Technologies FCPR, Mayo Clinic Health Solutions, Medevaq, Medical Device Consultants, Inc., Medical Leaders Company, Ltd., MedicineLodge, Inc., MPM Capital, Musculoskeletal Transplant Foundation, NDI, Nippon Sigmax Company, Ltd., NUTEK Corp., Orbimed Advisors, Osteon, PFM, Pinnacle Ventures, Premier Research, Prism Venture Partners, Prospect Venture Partners, RBC Product Development, Sanderling Ventures, Scale Venture Partners, Sorin Group, Spectranetics, St. Jude Medical, Stryker, Synectic Engineering, Inc., Teijin America, Teijin Pharma, Ltd., Teleflex Medical Incorporated, TriPharma Development Corporation, Versant Ventures, W.L. Gore & Associates, Inc., York Medtech Partners, and Ziegler Meditech Equity Partners.
The event will kick off with a Pre-Conference Workshop hosted by Chris Velis of Medical Capital Advisors, entitled "Top 10 Tips for Planning your VC Funding and Exit," followed by an insightful State of the Device Industry Address by David Cassak, titled "A Market Analysis of Where Medical Technology Companies are Going." Also on the program on June 18th is an informative and interactive Panel Discussion entitled "How Large Companies Sustain Growth through M&A and Strategic Partnerships," with panelists to include Richard Dakers, VP, Franchise Development, Cordis, a Johnson & Johnson Company; Stanton Rowe, Corporate VP for Advanced Technologies, Edwards Lifesciences; and Matthew Jennings, Senior Vice President, Corporate Development, Teleflex.
A Venture Capital Perspective Panel Discussion is also featured on the first day of the program, entitled "Early Stage Investing, Financing and Exit Strategies: What are the Hot Deals Now and in the Future," moderated by Steve Levin, Executive Editor at Windhover Information, with panelists to include Trevor J. Moody, Partner, Frazier Healthcare Ventures; John Maroney, General Partner, Delphi Ventures; Luke Evnin, General Partner, MPM Capital; John Lonergan, Partner, Mach Ventures, LP; and Kevin Wasserstein, Managing Director, Versant Ventures. The first day is concluded with a Presenting Company Product Exhibition/Networking Reception.
On Thursday morning the 19th, a highly anticipated Emerging Markets for Medical Devices Panel Discussion will take place, titled "Mining China for Potential Investments," with panelists to include Immanuel Thangaraj, Managing Director, Essex Woodland Health Ventures; Dr. Nancy Chang, Managing Director, OrbiMed; Carin Fradin, Executive Director, Global Healthcare Group, UBS; and Michael Yi Zhang, Ph.D., Chairman, Otsuka (China) Investment Co. Ltd. Another valuable panel discussion featured that day and just added to the program is entitled "Real-life Case Studies of Successful Financings: How to be Successful in the Start-Up Trenches."
The efficiently structured In3 Summit program will also feature two educational Workshops for start-up companies, one entitled "Creating Effective Presentations: Tips for Developing, Honing and Enhancing Your Presentation Skills and Content Development," hosted by Standing Stone Partners, and the other, "The Impact of Recent Patent Infringement Decisions and Litigation Outcomes on Your Medical Device Company," hosted by Knobbe Martens.
In3 Summit co-sponsors include the AdvaMed Emerging Growth Company Council (EGCC), Battelle, Business Wire, Knobbe Martens, MDMA, Medmarc and The Hartford, Medical Capital Advisors, The MedTech Group, Ronald Trahan Associates, Summit Corporate Services, and F-D-C Reports' The Gray Sheet.
Medtech Insight and its parent company, Windhover Information, have established a reputation as holding the premier forums worldwide for discerning senior executives in the medical device, diagnostics, biotech, and pharmaceutical business development and investment communities to meet and screen promising early-stage life sciences companies in need of funding, acquisition and/or strategic partnership, and to network with key decision makers in the industry. Over 1350 emerging medical technology company presenters and over 7200 attendees have participated at In3 events over the past 7 years.
Medtech Insight and Windhover Information will also be holding their annual "Investment In Innovation (In3) East" conference at the Westin Copley Place in Boston, MA, October 22-24. For more information on this event, please call Medtech Insight or visit the company's website at www.medtechinsight.com.
####
About Medtech Insight
Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace.
For more information, please click here
Contacts:
Medtech Insight, a division of Windhover Information Inc.
Kristy Grimes
480-985-9512 or 888-202-5939 toll-free in the U.S.
www.meddevicesummit.com
Copyright © Business Wire 2008
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||